PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34144673-0	2021	Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.	Cisplatin	0-9	CD4 molecule	Homo sapiens	61-64	
19020751-8	2008	Two CDDP-resistant pancreatic cancer cell line SUIT-2 variants, SUIT-2-CD3 and SUIT-2-CD4, were established by continuously administering 10 nM CDDP to SUIT-2 cell lines for 3 and 4 months, respectively.	Cisplatin	4-8	CD4 molecule	Homo sapiens	79-89	
35526096-8	2022	The immune profiling analysis of peripheral blood reveals an increased abundance of LAG-3hiPD-1hi memory CD4+T cell subset in relapsed cholangiocarcinoma patients after gemcitabine plus cisplatin therapy, which are more responsive to ABL501.	Cisplatin	186-195	CD4 molecule	Homo sapiens	105-108	
35433455-14	2022	CellMinor analysis showed that the CD4 mRNA expression level dramatically climbed with increased sensitivity of tumor cells to NAC drugs such as cyclophosphamide, cisplatin, and carboplatin (p"s < 0.05).	Cisplatin	163-172	CD4 molecule	Homo sapiens	35-38	
32878426-10	2021	The density of tumor margin-infiltrating FoxP3- CD4+ helper T cells may be associated with clinical outcomes in BTC patients treated with gemcitabine plus cisplatin.	Cisplatin	155-164	CD4 molecule	Homo sapiens	48-51	
30952714-10	2019	Furthermore, anti-PD-L1 alone and in combination with cisplatin, but not cisplatin alone, induced interferon-gamma-producing CD4+ T-cells.	Cisplatin	54-63	CD4 molecule	Homo sapiens	125-128	
32957741-0	2020	Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials.	Cisplatin	143-152	CD4 molecule	Homo sapiens	16-19	
28251947-0	2017	[Cisplatin-induced apoptotic endonuclease EndoG inhibits telomerase activity and causes malignant transformation of human CD4+ T lymphocytes].	Cisplatin	1-10	CD4 molecule	Homo sapiens	122-125	
28251947-5	2017	The aim of this study was to determine the ability of a DNA-damaging compound, cisplatin, to induce EndoG and its influence on alternative splicing of hTERT and telomerase activity in human CD4+ T lymphocytes.	Cisplatin	79-88	CD4 molecule	Homo sapiens	190-193	
25531529-8	2014	Treatment with cisplatin, CpG and PADRE also enhanced the generation of PADRE-specific CD4+ T cells and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci.	Cisplatin	15-24	CD4 molecule	Homo sapiens	87-90	
25659373-1	2015	OBJECTIVE: To investigate the effect of gemcitabine plus cisplatin chemotherapy on the percentage of CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) regulatory T cells (Tregs) in the peripheral blood of patients with nonsmall-cell lung cancer (NSCLC).	Cisplatin	57-66	CD4 molecule	Homo sapiens	101-104	
25659373-7	2015	Percentages of CD4(+)CD25(+)FOXP3(+) and CD8(+)CD28(-) Tregs were significantly reduced following gemcitabine plus cisplatin chemotherapy.	Cisplatin	115-124	CD4 molecule	Homo sapiens	15-18	
21822560-8	2012	CONCLUSION: Neoadjuvant chemotherapy utilizing 5-fluorouracil and cisplatin in esophageal squamous cell carcinoma is useful to induce CD4 and CD8 T lymphocytes in the tumor microenvironment and to maintain HLA class I expression levels in combination with its direct cytotoxic effects.	Cisplatin	66-75	CD4 molecule	Homo sapiens	134-137	
23600838-5	2013	Surprisingly, when the functional consequence of chemotherapy-treated CD14(+) monocytes and their capacity to activate CD4(+) T responders cells were investigated, cisplatin-treated monocytes gave rise to increased T cell proliferation.	Cisplatin	164-173	CD4 molecule	Homo sapiens	119-122	
21949094-6	2011	In contrast, administration of recombinant IL-33 (rIL-33) exacerbated cisplatin-induced AKI, measured by an increase in CD4 T cell infiltration, serum creatinine, ATN, and apoptosis; this did not occur in CD4-deficient mice, suggesting that CD4 T cells mediate the injurious effect of IL-33.	Cisplatin	70-79	CD4 molecule	Homo sapiens	120-123	
21949094-6	2011	In contrast, administration of recombinant IL-33 (rIL-33) exacerbated cisplatin-induced AKI, measured by an increase in CD4 T cell infiltration, serum creatinine, ATN, and apoptosis; this did not occur in CD4-deficient mice, suggesting that CD4 T cells mediate the injurious effect of IL-33.	Cisplatin	70-79	CD4 molecule	Homo sapiens	205-208